Dudediligence.

Stoke Therapeutics, Inc

STOKNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$4.9MSep ’24$22.6MDec ’24$158.6MMar ’25$13.8MJun ’25$10.6MSep ’25$1.4MDec ’25$6.2MMar ’26$9.3MJun ’26
Net income, by quarter
−$26.4MSep ’24−$10.5MDec ’24$112.9MMar ’25−$23.5MJun ’25−$38.3MSep ’25−$57.9MDec ’25−$50.0MMar ’26−$61.6MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on file$12.4M$8.8M$36.6M$184.4M
Operating income−$86.1M−$104.4M−$114.8M−$101.4M−$20.6M
Net income−$85.8M−$101.1M−$104.7M−$89.0M−$6.9M
Operating cash flow−$66.9M−$31.9M−$81.1M−$86.9M$45.6M
Free cash flow−$68.1M−$35.8M−$82.7M−$87.1M$44.9M
Cash$144.9M$113.6M$191.4M$128.0M$84.2M
Shares outstanding36.9M39.4M45.9M54.0M58.9M